Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branford

Showing results (411-420 of 480) with videos related to

Pageof 48
Sort By:
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Cancers|December 16, 2020
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia PatientsUlf Schmitz, Jaynish S Shah, Bijay P Dhungel, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Blood|August 9, 2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Irene Colavita, Concetta Quintarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Leukemia|October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsDavid M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
British Journal of Haematology|December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T Yeung, Andrew P Grigg, John Reynolds, et al.
Scientific Reports|May 28, 2017
A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasmD A Casolari, T Nguyen, C M Butcher, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Pageof 48

Showing results (411-420 of 480) with videos related to

Sort By:
Pageof 48
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Cancers|December 16, 2020
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia PatientsUlf Schmitz, Jaynish S Shah, Bijay P Dhungel, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Blood|August 9, 2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Irene Colavita, Concetta Quintarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Leukemia|October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsDavid M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
British Journal of Haematology|December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T Yeung, Andrew P Grigg, John Reynolds, et al.
Scientific Reports|May 28, 2017
A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasmD A Casolari, T Nguyen, C M Butcher, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Pageof 48